Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated May 12, 2025, titled "Press Release".
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 7.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics reported strong FY25 results with revenue rising 16% year-on-year to ₹717 crore, driven by higher patient volumes and competitive pricing across its diagnostic network. Profit after tax (PAT) surged 37% to ₹78 crore, the highest growth since listing, while EBITDA grew 34% to ₹196 crore with margins expanding to 27% from 24% the previous year. EPS jumped 36% to ₹23.56, and the board recommended a 55% dividend. The company is transitioning to an asset-light model through partnerships with Medikabazaar and United Imaging for over 30 imaging machines on deferred payment, and is expanding into PET-CT oncology services via investment in Apulki Healthcare. Management highlighted a 75% tender win ratio across PPP contracts in 12 states for pathology and 19 states for radiology.
Strong across-the-board growth in revenue, profitability, and margins signals robust operational momentum that is likely to be viewed positively by the market. The asset-light pivot and PPP tender wins support the case for sustained growth and improved return ratios going forward.